Skip to main content
padlock icon - secure page this page is secure

Open Access Tumor Targeting

Download Article:
 Download
(PDF 1,217.3 kb)
 
Cancer chemotherapy relies on the expectation that anti-cancer drugs will preferentially kill rapidly dividing tumor cells, rather than normal cells. Since a large portion of the tumor cells has to be killed in order to obtain and maintain a complete remission, large doses of drugs are typically used, with significant toxicity towards proliferating non-malignant cells. Our research focuses on the targeted delivery of therapeutic agents to the tumor environment by means of specific ligands (antibodies or small organic binding molecules) to tumor-associated antigens. In most cases, we target accessible antigens (such as the EDB domain of fibronectin or the C domain of tenascin-C) which are abundantly expressed around tumor blood vessels, but virtually undetectable in normal tissues.

12 References.

No Supplementary Data.
No Article Media
No Metrics

Keywords: ANGIOGENESIS; ANTIBODY ENGINEERING; ENCODED SELF-ASSEMBLING CHEMICAL LIBRARIES; HUMAN ANTIBODIES; TUMOR TARGETING

Document Type: Research Article

Publication date: October 1, 2004

More about this publication?
  • International Journal for Chemistry and Official Membership Journal of the Swiss Chemical Society (SCS) and its Divisions

    CHIMIA, a scientific journal for chemistry in the broadest sense, is published 10 times a year and covers the interests of a wide and diverse readership. Contributions from all fields of chemistry and related areas are considered for publication in the form of Review Articles and Notes. A characteristic feature of CHIMIA are the thematic issues, each devoted to an area of great current significance.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Information for Advertisers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more